Skip to main content
Journal ArticleOPEN ACCESS

Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: Results of a phase I randomized, placebo-controlled trial

Arthritis Research and Therapy (2012) 14(1)
DOI: 10.1186/ar3554
28Citations
Citations of this article
79Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: Pateclizumab (MLTA3698A) is a humanized mAb against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis. This study was conducted to assess the safety, tolerability,

Cite

CITATION STYLE

APA

Emu, B., Luca, D., Offutt, C., Grogan, J. L., Rojkovich, B., Williams, M. B., … Davis, J. C. (2012). Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: Results of a phase I randomized, placebo-controlled trial. Arthritis Research and Therapy, 14(1). https://doi.org/10.1186/ar3554

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free